Pharma Equity Group Reports Improved First Half Results
Pharma Equity Group A/S (PEG.CO) reported a smaller net loss for the first half of the year and reiterated its guidance for fiscal 2025.
Financial Performance for the Six Months Ended June 30
For the six months ended June 30, the company posted a net loss of DKK9.495 million, improved from a DKK12.901 million loss in the same period a year earlier. Loss before tax was DKK9.997 million, down from DKK13.919 million in the prior-year period.
Operating Loss
Operating loss for H1 amounted to DKK8.568 million, against DKK11.686 million a year ago.
Outlook for Fiscal 2025
Looking ahead, Pharma Equity Group expects a pre-tax loss of between DKK4 million and DKK7 million for fiscal 2025, with projected revenue of DKK11 million.
Fiscal 2024 Results
For fiscal 2024 the company recorded a pre-tax loss of DKK26.237 million and reported revenue of DKK000.00 million.
Contact Information
For comments and feedback, contact: [email protected]